Equities analysts expect SCYNEXIS Inc (NASDAQ:SCYX) to post ($0.19) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for SCYNEXIS’s earnings, with estimates ranging from ($0.24) to ($0.16). SCYNEXIS posted earnings per share of ($0.27) during the same quarter last year, which suggests a positive year-over-year growth rate of 29.6%. The company is expected to announce its next quarterly earnings report on Tuesday, November 6th.

On average, analysts expect that SCYNEXIS will report full year earnings of ($0.77) per share for the current financial year, with EPS estimates ranging from ($0.88) to ($0.67). For the next year, analysts forecast that the company will report earnings of ($0.61) per share, with EPS estimates ranging from ($0.71) to ($0.52). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow SCYNEXIS.

SCYNEXIS (NASDAQ:SCYX) last posted its earnings results on Thursday, August 9th. The company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.06). The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.08 million. SCYNEXIS had a negative return on equity of 105.78% and a negative net margin of 12,011.72%.

SCYX has been the topic of a number of research reports. HC Wainwright set a $5.00 price target on SCYNEXIS and gave the stock a “buy” rating in a research note on Wednesday, July 11th. Needham & Company LLC upgraded SCYNEXIS from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Wednesday, July 11th. Canaccord Genuity initiated coverage on SCYNEXIS in a research note on Friday, June 29th. They issued a “buy” rating and a $4.00 price target on the stock. Maxim Group initiated coverage on SCYNEXIS in a research note on Wednesday, June 27th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, LADENBURG THALM/SH SH initiated coverage on SCYNEXIS in a research note on Thursday, May 24th. They issued a “buy” rating and a $9.00 price target on the stock. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $5.14.

Shares of SCYX stock traded down $0.04 on Monday, reaching $1.30. The stock had a trading volume of 102,137 shares, compared to its average volume of 244,015. The company has a market cap of $63.00 million, a P/E ratio of -1.29 and a beta of 0.39. SCYNEXIS has a 1 year low of $1.05 and a 1 year high of $2.50. The company has a debt-to-equity ratio of 0.35, a current ratio of 4.30 and a quick ratio of 4.30.

In other news, CEO Marco Taglietti purchased 25,000 shares of the company’s stock in a transaction dated Thursday, August 23rd. The shares were purchased at an average cost of $1.29 per share, for a total transaction of $32,250.00. Following the purchase, the chief executive officer now directly owns 429,000 shares in the company, valued at approximately $553,410. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.25% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kabarec Financial Advisors Ltd. purchased a new position in SCYNEXIS during the second quarter valued at $130,000. Renaissance Technologies LLC purchased a new position in SCYNEXIS during the second quarter valued at $190,000. BlackRock Inc. lifted its position in SCYNEXIS by 61.5% during the second quarter. BlackRock Inc. now owns 180,751 shares of the company’s stock valued at $296,000 after purchasing an additional 68,830 shares in the last quarter. Iguana Healthcare Management LLC lifted its position in SCYNEXIS by 60.0% during the first quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock valued at $536,000 after purchasing an additional 150,000 shares in the last quarter. Finally, Rock Springs Capital Management LP lifted its position in SCYNEXIS by 7.9% during the first quarter. Rock Springs Capital Management LP now owns 820,000 shares of the company’s stock valued at $1,099,000 after purchasing an additional 60,000 shares in the last quarter. Institutional investors own 41.70% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.

Recommended Story: How are Outstanding Shares Different from Authorized Shares?

Get a free copy of the Zacks research report on SCYNEXIS (SCYX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.